Liebe Mitbetroffene,
Günter Feik sei herzlich gedankt für den Link zum Kongress der Europäischen Gesellschaft für Urologie in Berlin. Die Abstracts sind eine wahre Fundgrube für verschiedenste Studien, die uns betreffen.
Zahlreiche Studien beschäftigen sich mit der RPE als Option für Patienten mit T3-Tumoren, denen man landläufig von einer OP abrät. Die an anderer Stelle ja schon mehrfach geführten Diskussionen können durch die Abstracts neue Nahrung erhalten.
Ich möchte euch hier nur ein Beispiel bringen, das Ratsuchenden auf der Suche nach Therapien von Nutzen sein kann.
Gruß
Wassermann
Outcome of patients with locally advanced prostate cancer (pT3pN0) after radical prostatectomy
Zwergel, U.1, Suttmann, H.1, Lehmann, J.2, Hack, M.1, Stoeckle, M.1
1Saarland University, Dept. of Urology and Pediatric Urology, Homburg/Saar, Germany, 2Städtisches Krankenhaus Kiel GmbH, Dept of Urology, Kiel, Germany
Introduction & Objectives: Since there exists more and more experience and comfort with radical surgery the interest in approaching locally advanced prostate cancer (Pca) with prostatectomy has increased. We assessed the outcome of our pT3 patients after surgery, especially comparing pT3bpN0 prostate cancer with pT3apN0.
Material & Methods: A total of 536 men who underwent radical prostatectomy for Pca between January 1994 and January 2006 were found to have pT3 disease, lymph node positive patients were excluded. pT3a stage was found in 353/536 patients (65.8%) and pT3b stage in 183/536 patients (34.2%). About half of them (54%) were further treated with androgen ablation therapy. Life tables were calculated to determine 10 and 15 year overall and cancer specific survival rates. Progression-free survival rates accounted for PSA increase, development of local recurrence, distant metastases documented by bone scan and/or radiographic examination.
Results: Median patient age was 64.6 years (range 44 to 79). Mean follow-up was 37.2 months (median of 21.2 months). Overall (and cause specific) survival probabilities at 10 and 15 years were 77% (92%) and 52% (75%), respectively. When comparing Pca patients with and without seminal vesicle invasion, not only preoperative PSA levels and Gleason scores of the prostatectomy specimen were significantly different, but pT3b patients also had significant inferior outcome than pT3a patients (overall progression-free survival rates after 10 years: 53% vs 26%).
Conclusions: Since 75% of our patients were not likely to die from prostate cancer within the following 15 years after surgery despite histological evidence of locally advanced tumor, radical prostatectomy (with or without hormonal therapy) is a viable option for these patients, particularly in view of long-term survival. But the outcome of those men with seminal vesicle invasion (pT3b) is associated with a significantly poorer prognosis.
Günter Feik sei herzlich gedankt für den Link zum Kongress der Europäischen Gesellschaft für Urologie in Berlin. Die Abstracts sind eine wahre Fundgrube für verschiedenste Studien, die uns betreffen.
Zahlreiche Studien beschäftigen sich mit der RPE als Option für Patienten mit T3-Tumoren, denen man landläufig von einer OP abrät. Die an anderer Stelle ja schon mehrfach geführten Diskussionen können durch die Abstracts neue Nahrung erhalten.
Ich möchte euch hier nur ein Beispiel bringen, das Ratsuchenden auf der Suche nach Therapien von Nutzen sein kann.
Gruß
Wassermann
This abstract was presented during the past 22nd Annual EAU Congress, Berlin, 21-24 March 2007 | ||
Session: | Outcome of radical prostatectomy 1 | |
Date: | Wednesday March 21, 2007 from 12:45 to 14:15 | |
Room: | Room 15B |
Zwergel, U.1, Suttmann, H.1, Lehmann, J.2, Hack, M.1, Stoeckle, M.1
1Saarland University, Dept. of Urology and Pediatric Urology, Homburg/Saar, Germany, 2Städtisches Krankenhaus Kiel GmbH, Dept of Urology, Kiel, Germany
Introduction & Objectives: Since there exists more and more experience and comfort with radical surgery the interest in approaching locally advanced prostate cancer (Pca) with prostatectomy has increased. We assessed the outcome of our pT3 patients after surgery, especially comparing pT3bpN0 prostate cancer with pT3apN0.
Material & Methods: A total of 536 men who underwent radical prostatectomy for Pca between January 1994 and January 2006 were found to have pT3 disease, lymph node positive patients were excluded. pT3a stage was found in 353/536 patients (65.8%) and pT3b stage in 183/536 patients (34.2%). About half of them (54%) were further treated with androgen ablation therapy. Life tables were calculated to determine 10 and 15 year overall and cancer specific survival rates. Progression-free survival rates accounted for PSA increase, development of local recurrence, distant metastases documented by bone scan and/or radiographic examination.
Results: Median patient age was 64.6 years (range 44 to 79). Mean follow-up was 37.2 months (median of 21.2 months). Overall (and cause specific) survival probabilities at 10 and 15 years were 77% (92%) and 52% (75%), respectively. When comparing Pca patients with and without seminal vesicle invasion, not only preoperative PSA levels and Gleason scores of the prostatectomy specimen were significantly different, but pT3b patients also had significant inferior outcome than pT3a patients (overall progression-free survival rates after 10 years: 53% vs 26%).
Conclusions: Since 75% of our patients were not likely to die from prostate cancer within the following 15 years after surgery despite histological evidence of locally advanced tumor, radical prostatectomy (with or without hormonal therapy) is a viable option for these patients, particularly in view of long-term survival. But the outcome of those men with seminal vesicle invasion (pT3b) is associated with a significantly poorer prognosis.
Kommentar